As early as 2011 and 2012, two multitarget c-Met inhibitors, crizotinib and cabozantinib, were approved for the treatment of NSCLC and medullary thyroid cancer (MTC) as well as RCC, respectively.49,50 However, the indications are not based on their ability to target c-Met but are due to the inhibitory effect of crizotinib on the ALK fusion protein and the multikinase inhibitory activity of cabozantinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.